Skip to main content
Article
Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
Journal for ImmunoTherapy of Cancer (2015)
  • Yoshinobu Koguchi, Earle A. Chiles Research Institute, Portland, USA
  • Helena Hoen, Earle A. Chiles Research Institute, Portland, USA
  • Shelly Bambina, Earle A. Chiles Research Institute, Portland, USA
  • Michael Rynning, R&D Systems, Minneapolis, USA
  • Richard Fuerstenberg, R&D Systems, Minneapolis, USA
  • Zipei Feng, Earle A. Chiles Research Institute, Portland, USA
  • Bernard Fox, Earle A. Chiles Research Institute, Portland, USA
  • Carlo Bifulco, Earle A. Chiles Research Institute, Portland, USA
  • Brendan D Curti, Providence Portland Medical Center
  • Walter Urba, Earle A. Chiles Research Institute, Portland, USA
  • Christina Milburn, Bristol-Myers Squibb
  • Alan J Korman, Bristol-Myers Squibb
  • Keith S Bahjat, Earle A. Chiles Research Institute, Portland, USA
Publication Date
November 4, 2015
DOI
10.1186/2051-1426-3-S2-P96
Citation Information
Yoshinobu Koguchi, Helena Hoen, Shelly Bambina, Michael Rynning, et al.. "Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab" Journal for ImmunoTherapy of Cancer Vol. 3 Iss. 2 (2015) p. 96
Available at: http://works.bepress.com/carlo-bifulco/99/